



TECHNICAL DATA SHEET

Orgasol[®] 1002 D NAT 1



MAIN APPLICATIONS

Rubber coatings; toughening agent in epoxy structures

ORGASOL[®] 1002 D NAT 1 is a **spheroidal powder** of polyamide 6, with **20 µm** as average diameter and a **narrow particle size distribution**. An extremely high level of quality is achieved thanks to our rigorous control of particle size distribution, providing **excellent consistency in performance**.

ORGASOL[®] 1002 D NAT 1 has a **high Melting Temperature**, above 210°C. The shape of the particles and the particle size distribution are preserved even when processed at high temperatures. That is the reason why it can be used as **slipping agent in rubber coating** or as **toughening agent in thin-layered epoxy structures** (for example in carbon fibers reinforced composites or structural adhesives).

CHARACTERISTICS

METHOD

Appearance:	White spheroidal powder	Visual
Average diameter:	20 microns	ISO 13319
Particle size distribution:		
Fine particles < 10 microns	10 max. %	ISO 13319
Coarse particles > 30 microns	15 max. %	ISO 13319
Average Specific Surface Area:	2 m ² /g	ISO 9277
Apparent density unpacked:	0.425 g/cm ³	ISO 1068
Melting point:	217 °C	ISO 11357-3

PACKAGING

20 Kg multilayers bags

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Headquarters: Arkema France
420 rue d'Estienne d'Orves
92705 Colombes Cedex – France
Tel.: 33 (0)1 49 00 80 80
Fax: 33 (0)1 49 00 83 96
arkema.com